Fast Track to Vaccines: How Systems Biology Speeds Drug Development (preview)

Aids researchers and advocates were devastated in 2007, when a much anticipated vaccine against HIV unexpectedly failed to protect anyone in a clinical trial of 3,000 people. Even worse, the experimental inoculation, developed with money from the Merck pharmaceutical company and the National Institute of Allergy and Infectious Diseases, actually increased the chances that some people would later acquire HIV

Excerpt from:
Fast Track to Vaccines: How Systems Biology Speeds Drug Development (preview)